Lisa M. McShane

National Institutes of Health

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index89

i10-index180

Publications391

Citations57,510

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 40

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
JCO Precision Oncology · 2026-06-01
Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non–small cell lung cancer (NSCLC) study.
Journal of Clinical Oncology · 2026-05-28
Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial.
Journal of Clinical Oncology · 2026-05-27
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Clinical Cancer Research · 2026-01-20 · 1 citations
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images
Modern Pathology · 2026-01-05 · 3 citations
Supplementary Table 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Data from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Table 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Table 3 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Data 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
2025-11-25
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025-11-25
Phase II Study of Vismodegib in Patients With SMO- or PTCH1 -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
JCO Precision Oncology · 2025-10-01
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
JCO Precision Oncology · 2025-08-01 · 1 citations
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
Clinical Cancer Research · 2025-06-27 · 4 citations
Modernizing Research and Evidence Consensus Definitions
JAMA Network Open · 2025-06-17 · 7 citations
Abstract P2-02-18: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project
Clinical Cancer Research · 2025-06-13 · 1 citations

Open author page on OpenAlex →